0001610717-24-000433.txt : 20240822 0001610717-24-000433.hdr.sgml : 20240822 20240822175948 ACCESSION NUMBER: 0001610717-24-000433 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240820 FILED AS OF DATE: 20240822 DATE AS OF CHANGE: 20240822 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ogden Christopher CENTRAL INDEX KEY: 0001914523 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 241233032 MAIL ADDRESS: STREET 1: C/O CYTOMX THERAPEUTICS, INC. STREET 2: 151 OYSTER POINT BLVD., SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273521219 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml X0508 4 2024-08-20 0001501989 CytomX Therapeutics, Inc. CTMX 0001914523 Ogden Christopher C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400 SOUTH SAN FRANCISCO CA 94080 true Chief Financial Officer false Common Stock 2024-08-20 4 M 0 6875 0 A 110061 D Common Stock 2024-08-20 4 S 0 1984 1.2291 D 108077 D Performance Stock Units (PSUs) 2024-08-20 4 M 0 6875 0 D Common Stock 6875 0 D Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022. Includes 77,810 restricted stock units. The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone. /s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden 2024-08-22